Is Prenetics Global Limited (NASDAQ:PRE) a buy in 2026?
Hold. Prenetics Global Limited is a wait-and-watch at today's price, not a fresh buy.
Andrew Steele's longevity supplement play has real product momentum, but $18 already prices in flawless execution on a cash-burning consumer brand.
Where PRE is headed
By late 2027, Prenetics is either a $500M-$700M longevity brand riding the celebrity-founder wave, or a cautionary tale about how quickly consumer health hype compresses. The IM8 brand, co-founded with David Beckham, launched into the exact demographic slipstream that made AG1 a billion-dollar private company: affluent 35-55 year olds who now treat daily longevity powders as normal spend. Revenue more than doubled in the trailing twelve months and next year's consensus points to another 154% jump. That's the shape of a brand catching fire, not a business fighting for shelf space.
Read the full Compass Direction on PRE
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $20.83).
See the full PRE analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Prenetics Global Limited (NASDAQ:PRE) a buy in 2026?
Hold. Prenetics Global Limited is a wait-and-watch at today's price, not a fresh buy. Andrew Steele's longevity supplement play has real product momentum, but $18 already prices in flawless execution on a cash-burning consumer brand.
What is PRE's Compass Score?
Prenetics Global Limited scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for PRE?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PRE page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.